Patients’ clinical symptoms alleviated, IgG4‐RD RI and PGA decreased, as well as reduction of laboratory parameters including serum IgG, IgA, IgM, IgG4, IgE and ESR. This evidence concerns the gene CD79A and immunoglobulin G4-related sclerosing disease.